Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)
Status: Recruiting
Location: See all (72) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male or female (sex at birth).
• Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
• History of at least one self-reported unsuccessful dietary effort to lose body weight.
Locations
United States
Florida
South Broward Research LLC
RECRUITING
Miramar
Clinical Neuroscience Solution
RECRUITING
Orlando
Georgia
Hope Clin Res & Wellness
RECRUITING
Conyers
Illinois
Endeavor Health
RECRUITING
Skokie
Indiana
Midwest Inst For Clin Res
RECRUITING
Indianapolis
Missouri
StudyMetrix Research LLC
RECRUITING
City Of Saint Peters
North Carolina
UNC Eastowne Medical Office
RECRUITING
Chapel Hill
PharmQuest Life Sciences LLC
RECRUITING
Greensboro
Accellacare and KDCILM, LLC
NOT_YET_RECRUITING
Wilmington
New York
New York Gastroenterology Associates
RECRUITING
New York
Pennsylvania
UPA Ctr Weight and Eating Dis
RECRUITING
Philadelphia
Rhode Island
Clinical Res Collaborative
RECRUITING
Cumberland
South Carolina
Medical Uni of SC Charleston
RECRUITING
Charleston
Coastal Carolina Research Ctr
RECRUITING
North Charleston
Hillcrest Clinical Research
RECRUITING
Simpsonville
Texas
Amarillo Medical Specialists
RECRUITING
Amarillo
Velocity Clinical Res-Dallas
RECRUITING
Dallas
Care United Research, LLC
RECRUITING
Forney
Virginia
Washington Cntr Weight Mgmt
RECRUITING
Arlington
Health Res of Hampton Roads
RECRUITING
Newport News
Selma Medical Associates
RECRUITING
Winchester
Washington
Rainier Clin Res Ctr Inc
RECRUITING
Renton
Other Locations
Argentina
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
NOT_YET_RECRUITING
Buenos Aires
Instituto de Investigaciones Clínicas Córdoba
NOT_YET_RECRUITING
Córdoba
Sanatorio Esperanza
NOT_YET_RECRUITING
Esperanza, Santa Fe
CIPADI
NOT_YET_RECRUITING
Godoy Cruz
Instituto de Investigaciones Clinicas San Nicolás
NOT_YET_RECRUITING
San Nicolás
Fundación CESIM
NOT_YET_RECRUITING
Santa Rosa
Australia
Sydney Clinical Trials
NOT_YET_RECRUITING
Campbelltown
Heart of Australia
NOT_YET_RECRUITING
Chelmer
Sydney Cardiometabolic Centre
NOT_YET_RECRUITING
Liverpool
Hunter Diabetes Centre
NOT_YET_RECRUITING
Merewether
Belgium
HUB - Hôpital Erasme
NOT_YET_RECRUITING
Brussels
UZA - UZ Antwerpen - Department of Endocrinology
NOT_YET_RECRUITING
Edegem
UZ Gent - Endocrinologie - Diabetologie
NOT_YET_RECRUITING
Ghent
UZ Leuven - Endocrinology
NOT_YET_RECRUITING
Leuven
MECLINAS
NOT_YET_RECRUITING
Mechelen
AZ Delta - Roeselare
NOT_YET_RECRUITING
Roeselare
Canada
C-Health Partners
NOT_YET_RECRUITING
Calgary
Nova Scotia Hlth Halifax
NOT_YET_RECRUITING
Halifax
Milestone Research
NOT_YET_RECRUITING
London
G.A. Research Associates Ltd.
NOT_YET_RECRUITING
Moncton
Ocean West Research Clinic
NOT_YET_RECRUITING
Surrey
Denmark
Sanos Clinic - Gandrup
NOT_YET_RECRUITING
Gandrup
Steno Diabetes Center Nordjylland
COMPLETED
Gistrup
Gentofte Hospital - Center for Klinisk Metabolisk Forskning
NOT_YET_RECRUITING
Hellerup
Hillerød Endokrinologisk amb. H0652
NOT_YET_RECRUITING
Hillerød
Hvidovre Hospital Endokrinologisk forsknings afsnit 159
NOT_YET_RECRUITING
Hvidovre
Sanos Clinic - Vejle
NOT_YET_RECRUITING
Vejle
France
HOPITAL EUROPEEN GEORGES POMPIDOU_Service de nutrition et diabétologie
NOT_YET_RECRUITING
Paris
HCL-HOPITAL LYON SUD_Service d'Endocrinologie-Diabète-Nutrition
NOT_YET_RECRUITING
Pierre-bénite
CHU NANTES - HOPITAL NORD LAENNEC_Service d'Endocrinologie-Diabétologie-Nutrition
NOT_YET_RECRUITING
Saint-herblain
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE-HOPITAL RANGUEIL-Service de diabétologie et nutrition
NOT_YET_RECRUITING
Toulouse
CENTRE DE RECHERCHE CLINIQUE PORTES DU SUD_Service d'Endocrinologie-Diabétologie-Maladies Métaboliques
NOT_YET_RECRUITING
Vénissieux
Germany
Herz- und Diabeteszentrum NRW - Bad Oeynhausen
NOT_YET_RECRUITING
Bad Oeynhausen
Zentrum fuer klinische Studien Suedbrandenburg GmbH
NOT_YET_RECRUITING
Elsterwerda
MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien
NOT_YET_RECRUITING
Fulda
SMO.MD GmbH - Zentrum für klinische Studien
NOT_YET_RECRUITING
Magdeburg
Institut für Diabetesforschung Osnabrück
NOT_YET_RECRUITING
Osnabrück
Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann
NOT_YET_RECRUITING
Witten
United Kingdom
The Crouch Oak Family Practice
NOT_YET_RECRUITING
Addlestone
The Health Centre
NOT_YET_RECRUITING
Bradford-on-avon
EMS Healthcare
NOT_YET_RECRUITING
Cheshire
Fowey River Practice
NOT_YET_RECRUITING
Fowey
HMC Health - Heston - The Meadows Centre for Health
NOT_YET_RECRUITING
Hounslow
Kiltearn Medical Centre
NOT_YET_RECRUITING
Nantwich
Pickering Medical Practice
NOT_YET_RECRUITING
Pickering
Knowle House Surgery
NOT_YET_RECRUITING
Plymouth
The Adam Practice
NOT_YET_RECRUITING
Poole
Clifton Medical Centre
NOT_YET_RECRUITING
Rotherham
Staploe Medical Centre
NOT_YET_RECRUITING
Soham
Albany House Medical Centre
NOT_YET_RECRUITING
Wellingborough
Contact Information
Primary
Novo Nordisk
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Time Frame
Start Date: 2026-02-24
Estimated Completion Date: 2029-08-21
Participants
Target number of participants: 1150
Treatments
Experimental: NNC0487-0111
Participants will be randomized to receive 1 out of 4 different dose levels subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Placebo_comparator: Placebo
Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Related Therapeutic Areas
Sponsors
Leads: Novo Nordisk A/S